- Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
-
Micha JP, Rettenmaier MA, Bohart RD, Goldstein BH
- KMID: 2532770
- J Menopausal Med.
- 2022 Aug;28(2):47-51.
- doi: 10.6118/jmm.21035
Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast... -
- CITED
-
- Close
- SHARE
-
- Close
- Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer
-
Abaid LN, Rettenmaier MA, Brown JV, Micha JP, Mendivil A, Wabe MA, Goldstein
- KMID: 2177510
- J Gynecol Oncol.
- 2012 Jan;23(1):22-27.
- doi: 10.3802/jgo.2012.23.1.22
OBJECTIVE: The purpose of this retrospective study was to assess the tolerability and efficacy of sequential chemotherapy and radiotherapy for the treatment of high risk endometrial cancer. METHODS: We conducted a... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy and patient co-morbidity in ventral site hernia development
-
Rettenmaier MA, Abaid LN, Brown JV, Micha JP, Goldstein
- KMID: 2288591
- J Gynecol Oncol.
- 2009 Dec;20(4):246-250.
- doi: 10.3802/jgo.2009.20.4.246
OBJECTIVE: The risk factors associated with early ventral site hernia development following cancer surgery are ill defined and associated with an undetermined incidence. METHODS: We analyzed 1,391 gynecologic cancer patient charts... -
- CITED
-
- Close
- SHARE
-
- Close
